Skip to main
Order Wolverine

A considered, kiln-fired reading-room on the Wolverine blend — BPC-157 and TB-500 set down as two annotated specimen plates, with the regulatory and compounding-access record kept in the warm margin.

You can check the original papers

BPC-157 TB-500 sources show what researchers actually tested.

Researchers seeking better repair studied the substances on their own. The papers below describe their tests and the 2025-2026 reviews. FDA pages explain the pharmacy rules. You won't find a trial comparing the mixture with another treatment among these sources.

Go back to the research explanationReview the pharmacy question

The numbers beside claims lead you to the original papers

The early repair research tested separate substances before people paired them. Entries 1-6 cover BPC-157, TB-500, and the whole Thymosin Beta-4 protein. Entries 7-9 cover the 2025-2026 reviews of repair and safety. Entries 10-12 give FDA's papers for the Wolverine pharmacy question.

None of these papers tests your mixture against another treatment [7].

A number beside a claim is like a newspaper's page reference. You can use the number to find the paper listed below. The numbers on the pairing explanation and BPC-157 and TB-500 injury findings work that way.

So do numbers beside study amounts and short answers. The full papers and their identifying numbers follow below. Those long titles and numbers identify the source, rather than telling you how to treat an injury.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  6. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. ↗
  7. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical and 1 human; "shows promise" only from level IV-V evidence; no clinical safety data; no mention of TB-500 or combination use.) ↗
  8. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Animal-model promise but scarce human safety data and potential for serious harm; unapproved peptides including BPC-157 and TB-500 / thymosin beta-4 operate largely outside regulatory oversight.) ↗
  9. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human data limited to three small pilot studies; considered investigational given regulatory controversy and non-regulated availability.) ↗
  10. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; effective with the September 29, 2023 list update; cited safety rationale includes potential immunogenicity for certain routes and impurity/characterization complexity. Verified 2026-05-29.) ↗
  11. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B compounding framework and bulks-list/nomination process; the prescriber-evaluation access pathway. Verified 2026-05-29.) ↗
  12. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Published agenda lists BPC-157 and TB-500 among bulk drug substances being considered for inclusion on the 503A bulks list; a scheduled discussion of substances under evaluation, not a decision or outcome. Verified 2026-05-29.) ↗
  13. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  14. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  15. et al.. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗